Singapore Markets closed

Utilizing Real World Evidence Program in the New Cancer Drugs Segment to Ensure Long-Term Commercial Success – a Quantzig Case Study

Impact of Real World Evidence Analytics in the New Cancer Drugs Segment (Graphic: Business Wire) Multimedia Gallery URL

LONDON--(BUSINESS WIRE)--

Quantzig, a pure-play analytics solutions provider, has announced the completion of their latest engagement on real world evidence for a leading new cancer drugs manufacturer. The client, a leading player in the pharmaceutical sector was facing predicaments in leveraging real world data due to the availability of limited analytic skills. The new cancer drugs manufacturer wanted to gain a better understanding of drug efficacy over different patient cohorts.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180924005579/en/

According to the real world evidence experts at Quantzig, “The potential for real world evidence is on the rise, especially in the new cancer drugs segment to improve the entire drug development process.”

The rapid developments and innovative transformations taking place in the new cancer drugs segment will possibly be at the forefront of how real world evidence analytics impacts the process of drug development. Drug manufacturing firms can play a key role in actively shaping the role of real world evidence in the new cancer drugs development segment by expanding the industry collaborations and acting decisively, thereby, accelerating innovation in next-gen therapies.

Book a Solution Demo to see how Quantzig’s analytics solutions can help you.

The real world evidence program helped the client undertake an in-depth analysis of the new cancer drugs development pathways. The client was not only able to compare the cost and outcomes associated with the drugs manufactured by them, but also gained valuable insights into factors that impact the drug development process.

This real world evidence program provided benefits that helped the client to:

  • Enhance their analytics capabilities
  • Create the groundwork to apply advanced analytics and data manipulation techniques
  • To know more about the benefits of real world evidence program, speak to an expert

This real world evidence program offered predictive insights on:

  • Identifying factors for driving the future value of the business
  • Improving self-service analytic skills
  • To gain relevant insights and understand the scope of our solution, request a proposal

View the complete real world analytics summary here:

https://www.quantzig.com/content/real-world-evidence-new-cancer-drugs

About Quantzig

Quantzig is a global analytics and advisory firm with offices in the US, UK, Canada, China, and India. For more than 15 years, we have assisted our clients across the globe with end-to-end data modeling capabilities to leverage analytics for prudent decision making. Today, our firm consists of 120+ clients, including 45 Fortune 500 companies. For more information on all of Quantzig’s services and the solutions they have provided to Fortune 500 clients across all industries, please contact us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180924005579/en/

MULTIMEDIA AVAILABLE:https://www.businesswire.com/news/home/20180924005579/en/